EBMT 2025 | The changing landscape of hepatic VOD management: the role of the MDT in monitoring and management
In this video, Michelle Kenyon, King’s College Hospital NHS Foundation Trust, London, UK, briefly comments on the evolving landscape of hepatic veno-occlusive disease (VOD) management, highlighting the need to adapt risk assessment protocols to include patients receiving CAR T-cell therapy and gene therapy. Ms Kenyon emphasizes the importance of multidisciplinary team (MDT) communication and staff awareness in detecting and managing VOD. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So while VOD itself hasn’t changed, the patient populations who are at risk of developing veno-occlusive disease are starting to change. And we can’t ignore the emerging body of evidence around VOD development in patients receiving CAR-T and gene therapy, and so it’s very important that we make sure that these patients are included in our risk assessment protocols and ward management...
So while VOD itself hasn’t changed, the patient populations who are at risk of developing veno-occlusive disease are starting to change. And we can’t ignore the emerging body of evidence around VOD development in patients receiving CAR-T and gene therapy, and so it’s very important that we make sure that these patients are included in our risk assessment protocols and ward management. And I think also importantly, that the patients who are receiving these therapies are appropriately counseled for their risk of developing veno-occlusive disease.
So at my centre, we’ve implemented a really simple ward round protocol that has enabled us to detect this complication more promptly, enhance our multidisciplinary team communication and increase the general staff awareness of this complication.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
